Pharma Deals Review, Vol 2008, No 96 (2008)

Font Size:  Small  Medium  Large

Lundbeck Gains European Rights for Alzheimer’s Drug

Helen Scrutton

Abstract


H. Lundbeck has received European commercialisation rights for Myriad Genetics’ Phase III Alzheimer’s therapeutic, Flurizan® (tarenflurbil), agreeing to impressive financial terms in the process.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.